AstraZeneca takes on new CDK9 program
This article was originally published in Scrip
Executive Summary
AstraZeneca has acquired an early stage oncology/inflammation R&D program from German firm Probiodrug, which has decided to focus on its later-stage Alzheimer's disease drug development. The acquired technology, which includes intellectual property, a lead molecule and back-up compounds, is focused on the inhibition of cyclin-dependent kinase 9 (CDK9). Financial details were not disclosed.